If you have read anything at all about GHK-Cu, you have read the number. "Resets over 4,000 genes." "Affects 31.2% of the human genome." It appears on supplement labels, clinic websites and peptide forums, usually stated as flatly as a boiling point.

The number is real, in the sense that it was published. What almost nobody repeats is where it came from — and once you look, the claim gets much narrower and much more interesting. This piece is a myth-versus-evidence walkthrough of GHK-Cu research for Australian readers: what the gene data actually measured, what the human evidence does and doesn't cover, and where GHK-Cu sits with the TGA right now.

What is GHK-Cu, in one paragraph

GHK is a naturally occurring tripeptide — glycyl-L-histidyl-L-lysine — that binds copper(II) with high affinity to form GHK-Cu. It was first described by Loren Pickart in the 1970s as an activity in human plasma. In cell and animal models it has been linked to collagen and extracellular matrix synthesis, angiogenesis and anti-inflammatory signalling, which is why it turns up in cosmetic skincare. A widely quoted figure holds that plasma GHK falls from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60; worth knowing that this figure's citation trail leads back to Pickart's own review articles rather than a modern, independently replicated assay, so treat it as a legacy estimate rather than a settled measurement.

Where the "4,000 genes" claim actually comes from

The source is a 2014 paper by Pickart, Vasquez-Soltero and Margolina in BioMed Research International, titled "GHK and DNA: Resetting the Human Genome to Health."

Here is the critical detail: that paper was not a new laboratory experiment. It was an analysis of pre-existing gene expression profiles held in the Broad Institute's Connectivity Map (CMap) — a public library of microarray signatures generated by exposing cultured cell lines to thousands of compounds for a few hours. The authors reported that of about 13,424 genes assayed, 4,192 (roughly 31%) moved up or down by 50% or more after GHK exposure.

Three things follow from that, and all three matter:

1. The cells were immortalised cancer lines

The GHK signatures in CMap were generated in cultured human cancer cell lines — prostate (PC3) and breast (MCF7) — not in human skin, not in a wound, not in a person. Cancer cell lines are a screening tool. They are grown in plastic, in serum, with wildly abnormal genomes. A transcriptional response in PC3 cells is a hypothesis generator, not a description of what happens in your dermis.

2. "±50% change" is a cut-off, not a statistical test

A 50% up-or-down threshold on microarray data is a descriptive filter. It is not a p-value, it is not corrected for multiple comparisons across ~13,000 genes, and CMap profiles were generated from a small number of replicate exposures. Apply a permissive threshold to a genome-wide array and a large gene count is close to inevitable. That does not make the analysis wrong — it makes it exploratory.

3. "Resetting to health" is an interpretation, not a measurement

The array measures direction of change. Whether a given change is restorative, harmful or irrelevant is a judgement layered on top of the data. The 2014 paper is explicit that it is a review and analysis; the marketing that quotes it generally is not.

The COPD study people should quote instead

There is a stronger, more disciplined piece of work in this space that gets far less airtime. Campbell and colleagues, publishing in Genome Medicine in 2012, identified a 127-gene expression signature that tracked with regional severity of emphysematous lung destruction in human lung tissue. Genes rising with worsening destruction skewed toward inflammation; genes falling skewed toward tissue repair — TGF-β signalling, actin organisation, integrin signalling.

They then queried the Connectivity Map for compounds that reversed that signature. GHK came up. Crucially, they did not stop there: they went back to the bench and showed that GHK added to fibroblasts derived from COPD lung tissue restored actin cytoskeleton organisation, raised integrin β1 expression, and improved collagen gel contraction and remodelling.

That is a proper computational-to-experimental loop, and it is the intellectual origin of the "GHK reverses disease gene signatures" idea. It is also entirely in vitro. No patient with emphysema has been treated with GHK in a published controlled trial. Fourteen years on, that gap has not been closed.

What human evidence does exist — and its limits

The human data on GHK-Cu is almost entirely topical and cosmetic. Controlled cosmetic studies of copper-peptide creams have been run, and topical cosmetic use is lawful in Australia.

The most-cited recent human result is a small trial reported via press release in 2023 by Yuvan Research, a California company, testing its own stabilised topical gel formulation: 21 women, daily application, an average reported collagen increase of about 28% over three months, with the top quartile averaging 51%. Read that with the appropriate caveats — it is a press release rather than a peer-reviewed publication, the sample is tiny, the sponsor makes the product, and no independent group has replicated it. It is a reason to keep looking, not a reason to conclude anything.

A warning about trial registries

If you go looking for GHK-Cu trials yourself, be careful. Registry entries are self-submitted and are not peer-reviewed or verified. We recently encountered a posted GHK-Cu topical gel record whose listed sponsor we could not verify as a real research organisation, sitting in a cluster of near-identical peptide records filed from a single site. A registration number is not evidence of a trial, let alone of a result. Check that the sponsor exists before you cite anything.

Is GHK-Cu legal in Australia?

Two very different answers, depending on the route.

Topical cosmetics: yes. Copper-peptide serums and creams sold as cosmetics are legal in Australia, provided they carry cosmetic rather than therapeutic claims. That is the setting where essentially all of the human data sits.

Injectable GHK-Cu: no, it is unapproved. It is not on the Australian Register of Therapeutic Goods, and on 13 April 2026 the TGA issued a media release on the public health risks of unapproved peptide products — naming GHK-Cu alongside BPC-157, TB-500, CJC-1295 and retatrutide, noting these are often supplied in injectable form and flagging reports of severe allergic reactions. Unapproved products have not been assessed by the TGA for safety, quality or efficacy, and importing, manufacturing or supplying them commercially without authorisation is unlawful.

Worth adding a pharmacological point that the gene-count headlines skip entirely: GHK-Cu delivers copper. Topical application to skin and systemic injection are not the same exposure problem, and there is no published human pharmacokinetic or repeat-dose safety dataset for injected GHK-Cu to tell you what cumulative copper loading looks like. That absence is itself a finding.

The honest summary

GHK-Cu has a genuinely interesting mechanistic literature and one elegant computational-plus-bench study in COPD tissue. What it does not have is the thing the marketing implies: evidence that administering it to a living human "resets" thousands of genes toward health. The 4,192-gene figure describes cancer cells in a dish, filtered at a permissive threshold, in a re-analysis of public screening data.

That is not nothing. It is also not a clinical outcome. For more compound-by-compound breakdowns like this one, see our peptides index, or join the free updates list and we'll send new evidence reviews as they land.

FAQ

What is GHK-Cu used for?

GHK-Cu is used almost exclusively in topical cosmetic skincare, where copper-peptide serums are marketed for collagen support and skin appearance. Wider claims about wound healing, hair and lung repair rest on cell and animal research rather than completed human trials.

Does GHK-Cu really affect 4,000 genes?

The figure comes from a 2014 re-analysis of Broad Institute Connectivity Map data, which reported that about 4,192 of 13,424 assayed genes shifted by 50% or more. Those profiles were generated in cultured human cancer cell lines, not in human skin or living people, and a ±50% cut-off is a descriptive filter rather than a statistical test.

Is GHK-Cu legal in Australia?

Topical GHK-Cu sold as a cosmetic is legal in Australia. Injectable GHK-Cu is unapproved, is not on the ARTG, and was named in the TGA's April 2026 alert about the risks of unapproved peptide products.

Is there any human clinical trial evidence for GHK-Cu?

The human evidence is topical and small. Controlled cosmetic studies exist, and a 21-participant company-run trial reported via press release in 2023 claimed an average 28% collagen increase over three months — unreplicated, not peer-reviewed, and sponsored by the product's maker. No published controlled human trial supports injected GHK-Cu.

Sources

This article is independent information, not medical advice. Topical GHK-Cu is sold lawfully as a cosmetic in Australia; injectable GHK-Cu is not approved by the TGA, is not on the ARTG, and was named in the TGA's April 2026 unapproved-peptides alert. retatrutide.net.au is not affiliated with any manufacturer or supplier and does not sell or source peptides.